RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Recruiting · NCT06420973 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinoma, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, primary peritoneal carcinoma | Recruiting | Phase 2 | 2026-10-01 | NCT06420973 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University Cancer Hospital & Institute | 189 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hong Zheng | Beijing | China | 1 |